Braxia Scientific Corp.
BRAX
CNSX
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 23.33% | 33.49% | 30.37% | 19.82% | 48.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 23.33% | 33.49% | 30.37% | 19.82% | 48.34% |
| Cost of Revenue | 19.24% | 36.75% | 43.75% | 30.41% | 58.45% |
| Gross Profit | 54.17% | 12.76% | -39.87% | -33.17% | 0.13% |
| SG&A Expenses | -40.95% | -28.32% | -13.29% | -11.55% | 14.51% |
| Depreciation & Amortization | -12.57% | 104.60% | 1,058.27% | 2,180.65% | 2,192.59% |
| Other Operating Expenses | -23.08% | -23.08% | -23.08% | 280.00% | 290.00% |
| Total Operating Expenses | -30.02% | -14.57% | 0.94% | -0.43% | 28.24% |
| Operating Income | 43.60% | 25.37% | 5.36% | 4.67% | -23.97% |
| Income Before Tax | 24.36% | 18.06% | -2.43% | -2.73% | -125.25% |
| Income Tax Expenses | -202.24% | -202.24% | -202.24% | -202.24% | -- |
| Earnings from Continuing Operations | 25.21% | 18.85% | -1.68% | -1.99% | -124.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.21% | 18.85% | -1.68% | -1.99% | -124.41% |
| EBIT | 43.60% | 25.37% | 5.36% | 4.67% | -23.97% |
| EBITDA | 44.49% | 29.04% | 12.53% | 11.76% | -17.05% |
| EPS Basic | 38.26% | 36.65% | 22.76% | 22.12% | -43.75% |
| Normalized Basic EPS | 50.00% | 45.45% | 26.94% | 26.11% | 1.91% |
| EPS Diluted | 38.26% | 36.65% | 22.76% | 22.12% | -43.75% |
| Normalized Diluted EPS | 50.00% | 45.45% | 26.94% | 26.11% | 1.91% |
| Average Basic Shares Outstanding | 20.92% | 29.08% | 33.97% | 30.32% | 29.55% |
| Average Diluted Shares Outstanding | 20.92% | 29.08% | 33.97% | 30.32% | 29.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
